• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PD-1 通过抑制酪蛋白激酶 2 增加 PTEN 磷酸酶活性,同时降低 PTEN 蛋白稳定性。

PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2.

机构信息

Department of Hematology-Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

出版信息

Mol Cell Biol. 2013 Aug;33(16):3091-8. doi: 10.1128/MCB.00319-13. Epub 2013 Jun 3.

DOI:10.1128/MCB.00319-13
PMID:23732914
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3753920/
Abstract

Programmed death 1 (PD-1) is a potent inhibitor of T cell responses. PD-1 abrogates activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, but the mechanism remains unclear. We determined that during T cell receptor (TCR)/CD3- and CD28-mediated stimulation, PTEN is phosphorylated by casein kinase 2 (CK2) in the Ser380-Thr382-Thr383 cluster within the C-terminal regulatory domain, which stabilizes PTEN, resulting in increased protein abundance but suppressed PTEN phosphatase activity. PD-1 inhibited the stabilizing phosphorylation of the Ser380-Thr382-Thr383 cluster within the C-terminal domain of PTEN, thereby resulting in ubiquitin-dependent degradation and diminished abundance of PTEN protein but increased PTEN phosphatase activity. These effects on PTEN were secondary to PD-1-mediated inhibition of CK2 and were recapitulated by pharmacologic inhibition of CK2 during TCR/CD3- and CD28-mediated stimulation without PD-1. Furthermore, PD-1-mediated diminished abundance of PTEN was reversed by inhibition of ubiquitin-dependent proteasomal degradation. Our results identify CK2 as a new target of PD-1 and reveal an unexpected mechanism by which PD-1 decreases PTEN protein expression while increasing PTEN activity, thereby inhibiting the PI3K/Akt signaling axis.

摘要

程序性死亡受体 1(PD-1)是 T 细胞反应的有效抑制剂。PD-1 可阻断磷脂酰肌醇 3-激酶(PI3K)/Akt 通路的激活,但具体机制尚不清楚。我们发现,在 T 细胞受体(TCR)/CD3 和 CD28 介导的刺激下,PTEN 的 C 端调节域中的丝氨酸 380-苏氨酸 382-苏氨酸 383 簇通过酪蛋白激酶 2(CK2)发生磷酸化,从而稳定了 PTEN,导致其蛋白丰度增加但磷酸酶活性受到抑制。PD-1 抑制了 PTEN C 端结构域 Ser380-Thr382-Thr383 簇的稳定磷酸化,导致其泛素依赖性降解,蛋白丰度降低,但磷酸酶活性增加。这些对 PTEN 的影响是 PD-1 介导的 CK2 抑制的结果,并且在 TCR/CD3 和 CD28 介导的刺激过程中通过药理学抑制 CK2 而重现,而无需 PD-1。此外,PD-1 介导的 PTEN 蛋白丰度降低可通过抑制泛素依赖性蛋白酶体降解来逆转。我们的结果确定 CK2 为 PD-1 的新靶点,并揭示了 PD-1 降低 PTEN 蛋白表达同时增加 PTEN 活性从而抑制 PI3K/Akt 信号通路的一种意外机制。

相似文献

1
PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2.PD-1 通过抑制酪蛋白激酶 2 增加 PTEN 磷酸酶活性,同时降低 PTEN 蛋白稳定性。
Mol Cell Biol. 2013 Aug;33(16):3091-8. doi: 10.1128/MCB.00319-13. Epub 2013 Jun 3.
2
Protein kinase CK2/PTEN pathway plays a key role in platelet-activating factor-mediated murine anaphylactic shock.蛋白激酶 CK2/PTEN 通路在血小板激活因子介导的小鼠过敏性休克中发挥关键作用。
J Immunol. 2011 Jun 1;186(11):6625-32. doi: 10.4049/jimmunol.1100007. Epub 2011 Apr 29.
3
Estrogen receptor α induces down-regulation of PTEN through PI3-kinase activation in breast cancer cells.雌激素受体 α 通过激活 PI3-激酶诱导乳腺癌细胞中 PTEN 的下调。
Mol Med Rep. 2011 Mar-Apr;4(2):215-9. doi: 10.3892/mmr.2011.412. Epub 2011 Jan 3.
4
Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels.成人B细胞急性淋巴细胞白血病细胞尽管PTEN蛋白水平较高,但仍表现出PTEN活性降低以及PI3K/Akt通路的组成性过度激活。
Haematologica. 2014 Jun;99(6):1062-8. doi: 10.3324/haematol.2013.096438. Epub 2014 Feb 21.
5
Evaluation of CK2 inhibitor (E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid (TBCA) in regulation of platelet function.评价 CK2 抑制剂(E)-3-(2,3,4,5-四溴苯基)丙烯酸(TBCA)对血小板功能的调节作用。
Eur J Pharmacol. 2013 Nov 15;720(1-3):391-400. doi: 10.1016/j.ejphar.2013.09.064. Epub 2013 Oct 15.
6
Casein Kinase II (CK2), Glycogen Synthase Kinase-3 (GSK-3) and Ikaros mediated regulation of leukemia.酪蛋白激酶II(CK2)、糖原合酶激酶-3(GSK-3)与伊卡洛斯介导的白血病调控
Adv Biol Regul. 2017 Aug;65:16-25. doi: 10.1016/j.jbior.2017.06.001. Epub 2017 Jun 13.
7
The impact of PTEN regulation by CK2 on PI3K-dependent signaling and leukemia cell survival.CK2对PTEN的调控对PI3K依赖信号传导及白血病细胞存活的影响。
Adv Enzyme Regul. 2011;51(1):37-49. doi: 10.1016/j.advenzreg.2010.09.012. Epub 2010 Oct 28.
8
Phosphatase PTEN is inactivated in bovine aortic endothelial cells exposed to cyclic strain.在受到周期性拉伸的牛主动脉内皮细胞中,磷酸酶PTEN失活。
J Cell Biochem. 2007 Feb 1;100(2):515-26. doi: 10.1002/jcb.21085.
9
Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors.CK2 和 Notch1 对原发性 T 细胞急性淋巴细胞白血病中 PTEN 的调控:联合使用 CK2 和γ-分泌酶抑制剂的原理。
Haematologica. 2010 Apr;95(4):674-8. doi: 10.3324/haematol.2009.011999. Epub 2009 Dec 16.
10
Leptin-dependent phosphorylation of PTEN mediates actin restructuring and activation of ATP-sensitive K+ channels.瘦素依赖的PTEN磷酸化介导肌动蛋白重塑和ATP敏感性钾通道的激活。
J Biol Chem. 2009 Apr 3;284(14):9331-40. doi: 10.1074/jbc.M806774200. Epub 2009 Feb 10.

引用本文的文献

1
Programmed Death-1 Ligand 1 Domain Organization, Signaling Motifs, and Interactors in Cancer Immunotherapy.癌症免疫治疗中的程序性死亡-1配体1结构域组织、信号基序及相互作用分子
Cancers (Basel). 2025 May 12;17(10):1635. doi: 10.3390/cancers17101635.
2
Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications.免疫检查点分子:关于信号通路及免疫治疗意义的综述
Immun Inflamm Dis. 2025 Apr;13(4):e70196. doi: 10.1002/iid3.70196.
3
Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy.免疫检查点的翻译后修饰:开启癌症免疫治疗的新潜力。
Exp Hematol Oncol. 2025 Mar 14;14(1):37. doi: 10.1186/s40164-025-00627-6.
4
Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers.靶向PD-1/PD-L1信号通路用于癌症治疗:聚焦生物标志物。
Int J Mol Sci. 2025 Jan 31;26(3):1235. doi: 10.3390/ijms26031235.
5
Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape.胶质母细胞瘤中的免疫检查点途径:一个多样化且不断发展的领域。
Front Immunol. 2024 Sep 13;15:1424396. doi: 10.3389/fimmu.2024.1424396. eCollection 2024.
6
PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets.PD-1/LAG-3 共信号通路分析揭示 CBL 泛素连接酶为免疫治疗的关键靶点。
EMBO Mol Med. 2024 Aug;16(8):1791-1816. doi: 10.1038/s44321-024-00098-y. Epub 2024 Jul 19.
7
The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review.工程化 CAR-T 细胞与 PD-1 阻断联合免疫治疗在淋巴瘤和实体瘤中的协同作用:系统评价。
Front Immunol. 2024 May 10;15:1389971. doi: 10.3389/fimmu.2024.1389971. eCollection 2024.
8
Exosomal PD-L1 in cancer and other fields: recent advances and perspectives.外泌体 PD-L1 在癌症及其他领域的研究进展与展望
Front Immunol. 2024 Apr 25;15:1395332. doi: 10.3389/fimmu.2024.1395332. eCollection 2024.
9
The PD-1/PD-L1 Axis in the Biology of MASLD.PD-1/PD-L1 轴在 MASLD 生物学中的作用。
Int J Mol Sci. 2024 Mar 25;25(7):3671. doi: 10.3390/ijms25073671.
10
A Comprehensive Computational Insight into the PD-L1 Binding to PD-1 and Small Molecules.对程序性死亡配体1(PD-L1)与程序性死亡受体1(PD-1)及小分子结合的全面计算洞察
Pharmaceuticals (Basel). 2024 Feb 28;17(3):316. doi: 10.3390/ph17030316.

本文引用的文献

1
Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation.PD-1 对 Akt 和 Ras 通路的选择性作用调节细胞周期的分子成分并抑制 T 细胞增殖。
Sci Signal. 2012 Jun 26;5(230):ra46. doi: 10.1126/scisignal.2002796.
2
The PD-1 pathway in tolerance and autoimmunity.PD-1 通路在耐受和自身免疫中的作用。
Immunol Rev. 2010 Jul;236:219-42. doi: 10.1111/j.1600-065X.2010.00923.x.
3
Distinct roles for PTEN in prevention of T cell lymphoma and autoimmunity in mice.PTEN 在预防小鼠 T 细胞淋巴瘤和自身免疫中的独特作用。
J Clin Invest. 2010 Jul;120(7):2497-507. doi: 10.1172/JCI42382.
4
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells.PD-L1 调节诱导性调节 T 细胞的发育、维持和功能。
J Exp Med. 2009 Dec 21;206(13):3015-29. doi: 10.1084/jem.20090847. Epub 2009 Dec 14.
5
PD-1 signaling in primary T cells.初始T细胞中的PD-1信号传导。
Immunol Rev. 2009 May;229(1):114-25. doi: 10.1111/j.1600-065X.2009.00767.x.
6
PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability.PTEN的翻译后失活以及PI3K/Akt信号通路的过度激活维持原发性T细胞白血病的生存能力。
J Clin Invest. 2008 Nov;118(11):3762-74. doi: 10.1172/JCI34616. Epub 2008 Oct 1.
7
Co-existence of high levels of the PTEN protein with enhanced Akt activation in renal cell carcinoma.肾细胞癌中高水平PTEN蛋白与增强的Akt激活并存。
Biochim Biophys Acta. 2007 Oct;1772(10):1134-42. doi: 10.1016/j.bbadis.2007.07.001. Epub 2007 Jul 12.
8
Essential role for nuclear PTEN in maintaining chromosomal integrity.细胞核中PTEN在维持染色体完整性方面的重要作用。
Cell. 2007 Jan 12;128(1):157-70. doi: 10.1016/j.cell.2006.11.042.
9
NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN.NEDD4-1是一种针对PTEN的原癌基因泛素连接酶。
Cell. 2007 Jan 12;128(1):129-39. doi: 10.1016/j.cell.2006.11.039.
10
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms.细胞毒性T淋巴细胞相关抗原4(CTLA-4)和程序性死亡受体1(PD-1)通过不同机制抑制T细胞活化。
Mol Cell Biol. 2005 Nov;25(21):9543-53. doi: 10.1128/MCB.25.21.9543-9553.2005.